Halozyme Therapeutics Inc (HALO) Shares Outstanding 2006–TTM

Name: Halozyme Therapeutics Inc (HALO) shares outstanding history 2006-TTM
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

DATA UPDATED 2026-08-16

Halozyme Therapeutics Inc annual shares outstanding for fiscal 2025 was 124 million shares, a decrease of 3.9% from 129 million shares in fiscal 2024. All figures are reported results from public filings — no estimates or projections.

HALO Annual Shares Outstanding

Shares Outstanding (annual)	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Shares Outstanding (M)	—	124M	129M	134M	141M	147M	141M	144M	144M	139M	128M	127M	123M	113M	111M	103M	94M	87M	80M	74M	63M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

HALO Quarterly Shares Outstanding

Shares Outstanding (quarterly)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30
Shares Outstanding (M)	—	123M	118M	122M	124M	127M	129M	130M	129M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Shares Outstanding at Comparable Companies

EXEL Shares Outstanding — Exelixis Inc
CORT Shares Outstanding — Corcept Therapeutics Incorporated
ARWR Shares Outstanding — Arrowhead Pharmaceuticals Inc
MDGL Shares Outstanding — Madrigal Pharmaceuticals Inc
AXSM Shares Outstanding — Axsome Therapeutics Inc
SMMT Shares Outstanding — Summit Therapeutics PLC

More HALO metrics: Revenue · Gross Profit · Operating Income · Net Income · EPS · EBITDA · Free Cash Flow

All HALO financial statements → Interactive HALO charts →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.